Top Markets
Coin of the day
SynAct Pharma AB SynAct Pharma AB

SynAct Pharma AB

SYNACT
Rank in Stocks #20988
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS,... SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Γ–rebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Share Price
$2.22
Last synced: 2026-08-21
Market Cap
$117.70M
Change (1 day)
2.69%
Change (1 year)
17.26%
Country
SE
Trade SynAct Pharma AB (SYNACT)

Category

P/B ratio for SynAct Pharma AB (SYNACT)
P/B ratio as of 2026 TTM: 0
According to SynAct Pharma AB latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for SynAct Pharma AB from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH